{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:57:50Z","timestamp":1786985870784,"version":"build-2736575974"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["1R01HS018975-01A1"],"award-info":[{"award-number":["1R01HS018975-01A1"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["contemporaryclinicaltrials.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.cct.2015.03.006","type":"journal-article","created":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T20:00:36Z","timestamp":1428782436000},"page":"132-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD): Design and implementation of randomized clinical trial"],"prefix":"10.1016","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct01692743","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Raymond K.","family":"Cross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad","family":"Jambaulikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Langenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Kathleen","family":"Tracy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Regueiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene C.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.cct.2015.03.006_bb0005","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","article-title":"Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences","volume":"126","author":"Loftus","year":"2004","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cct.2015.03.006_bb0010","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1053\/j.gastro.2004.02.072","article-title":"From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation","volume":"126","author":"Sands","year":"2004","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.cct.2015.03.006_bb0015","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/01.mib.0000179467.01748.99","article-title":"Health-related quality of life in patients with inflammatory bowel disease measured with the Short Form-36: psychometric assessments and a comparison with general population norms","volume":"11","author":"Bernklev","year":"2005","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"10.1016\/j.cct.2015.03.006_bb0020","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/JOM.0b013e318181b8ca","article-title":"The direct and indirect cost burden of Crohn's disease and ulcerative colitis","volume":"50","author":"Gibson","year":"2008","journal-title":"J Occup Environ Med"},{"issue":"5","key":"10.1016\/j.cct.2015.03.006_bb0025","first-page":"1064","article-title":"Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey","volume":"98","author":"Longobardi","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cct.2015.03.006_bb0030","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1053\/j.gastro.2008.09.012","article-title":"Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults","volume":"135","author":"Kappelman","year":"2008","journal-title":"Gastroenterology"},{"issue":"15","key":"10.1016\/j.cct.2015.03.006_bb0035","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cct.2015.03.006_bb0040","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9343(02)01383-9","article-title":"Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis","volume":"114","author":"Kane","year":"2003","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.cct.2015.03.006_bb0045","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/j.1572-0241.2003.07522.x","article-title":"Patient nonadherence to medication in inflammatory bowel disease","volume":"98","author":"Sewitch","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.cct.2015.03.006_bb0050","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/j.1365-2036.2005.02429.x","article-title":"Polypharmacy and Crohn's disease","volume":"21","author":"Cross","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.cct.2015.03.006_bb0055","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/MCG.0b013e31802f19af","article-title":"Patient subjective assessment of drug side effects in inflammatory bowel disease","volume":"42","author":"Cross","year":"2008","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"10.1016\/j.cct.2015.03.006_bb0060","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/00054725-200311000-00003","article-title":"Evaluation of educational programs in inflammatory bowel disease","volume":"9","author":"Quan","year":"2003","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"10.1016\/j.cct.2015.03.006_bb0065","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1038\/ajg.2011.329","article-title":"Potential use of telemedicine to provide outpatient care for inflammatory bowel disease","volume":"106","author":"Krier","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"9286","key":"10.1016\/j.cct.2015.03.006_bb0070","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S0140-6736(01)06105-0","article-title":"Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial","volume":"358","author":"Robinson","year":"2001","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.cct.2015.03.006_bb0075","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1136\/gut.2010.220160","article-title":"E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided \u2018constant-care\u2019 approach","volume":"59","author":"Elkjaer","year":"2010","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.cct.2015.03.006_bb0080","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.cgh.2013.11.015","article-title":"Association between telephone activity and features of patients with inflammatory bowel disease","volume":"12","author":"Ramos-Rivers","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.cct.2015.03.006_bb0085","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1136\/gut.2003.034256","article-title":"A randomised controlled trial to assess the effectiveness and cost of a patient orientated self management approach to chronic inflammatory bowel disease","volume":"53","author":"Kennedy","year":"2004","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.cct.2015.03.006_bb0090","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/00004836-200603000-00006","article-title":"Acceptance of telemanagement is high in patients with inflammatory bowel disease","volume":"40","author":"Cross","year":"2006","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"10.1016\/j.cct.2015.03.006_bb0095","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10620-006-9523-4","article-title":"Feasibility and acceptance of a home telemanagement system in patients with inflammatory bowel disease: a 6-month pilot study","volume":"52","author":"Cross","year":"2007","journal-title":"Dig Dis Sci"},{"issue":"11","key":"10.1016\/j.cct.2015.03.006_bb0100","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1007\/s10620-008-0640-0","article-title":"Home telemanagement for patients with ulcerative colitis (UC HAT)","volume":"54","author":"Cross","year":"2009","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.cct.2015.03.006_bb0105","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/ibd.21795","article-title":"Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT)","volume":"18","author":"Cross","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cct.2015.03.006_bb0110","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/00365528909091339","article-title":"Classification of inflammatory bowel disease","volume":"170","author":"Lennard-Jones","year":"1989","journal-title":"Scand J Gastroenterol Suppl"},{"issue":"8167","key":"10.1016\/j.cct.2015.03.006_bb0115","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn's-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cct.2015.03.006_bb0120","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/01.MIB.0000215091.77492.2a","article-title":"Predicting the Crohn's disease activity index from the Harvey\u2013Bradshaw Index","volume":"12","author":"Best","year":"2006","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.cct.2015.03.006_bb0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/gut.43.1.29","article-title":"A simple clinical colitis activity index","volume":"43","author":"Walmsley","year":"1998","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.cct.2015.03.006_bb0130","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/gut.2004.056358","article-title":"Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis","volume":"54","author":"Higgins","year":"2005","journal-title":"Gut"},{"issue":"4 Pt 2","key":"10.1016\/j.cct.2015.03.006_bb0135","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0016-5085(79)90384-6","article-title":"Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI)","volume":"77","author":"Best","year":"1979","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cct.2015.03.006_bb0140","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1572-0241.2005.40641.x","article-title":"Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?","volume":"100","author":"Higgins","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cct.2015.03.006_bb0145","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ajg.2010.392","article-title":"The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn's and colitis organization: when to start, when to stop, which drug to choose, and how to predict response?","volume":"106","author":"D'Haens","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cct.2015.03.006_bb0150","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","article-title":"Practice Parameters Committee of the American College of G. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee","volume":"105","author":"Kornbluth","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cct.2015.03.006_bb0155","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1053\/j.gastro.2006.01.048","article-title":"American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease","volume":"130","author":"Lichtenstein","year":"2006","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cct.2015.03.006_bb0160","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cct.2015.03.006_bb0165","series-title":"Inflammatory bowel diseases","author":"Satsangi","year":"2003"},{"issue":"8","key":"10.1016\/j.cct.2015.03.006_bb0170","first-page":"971","article-title":"An index of disease activity in patients with ulcerative colitis","volume":"87","author":"Seo","year":"1992","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.cct.2015.03.006_bb0175","first-page":"1759","article-title":"Evaluation of disease activity in patients with moderately active ulcerative colitis: comparisons between a new activity index and Truelove and Witts' classification","volume":"90","author":"Seo","year":"1995","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cct.2015.03.006_bb0180","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00004836-198808000-00011","article-title":"The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study","volume":"10","author":"Boirivant","year":"1988","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"10.1016\/j.cct.2015.03.006_bb0185","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/0016-5085(86)90206-4","article-title":"A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease","volume":"91","author":"Brignola","year":"1986","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cct.2015.03.006_bb0190","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.22.7.571","article-title":"Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index","volume":"22","author":"Andre","year":"1981","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.cct.2015.03.006_bb0195","first-page":"17","article-title":"Determining disease activity in inflammatory bowel disease","volume":"6","author":"Cooke","year":"1984","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"10.1016\/j.cct.2015.03.006_bb0200","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/0016-5085(89)90905-0","article-title":"A new measure of health status for clinical trials in inflammatory bowel disease","volume":"96","author":"Guyatt","year":"1989","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cct.2015.03.006_bb0205","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/01.MIB.0000217768.75519.32","article-title":"Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn's disease","volume":"12","author":"Hlavaty","year":"2006","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.cct.2015.03.006_bb0210","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0016-5085(94)90585-1","article-title":"Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group","volume":"106","author":"Irvine","year":"1994","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cct.2015.03.006_bb0215","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3109\/00365527809182199","article-title":"A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis","volume":"13","author":"Powell-Tuck","year":"1978","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cct.2015.03.006_bb0220","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"issue":"12","key":"10.1016\/j.cct.2015.03.006_bb0225","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1111\/j.1572-0241.1999.01536.x","article-title":"The Crohn's and Colitis knowledge score: a test for measuring patient knowledge in inflammatory bowel disease","volume":"94","author":"Eaden","year":"1999","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cct.2015.03.006_bb0230","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1521\/jscp.1998.17.1.89","article-title":"Social constraints, intrusive thoughts and mental health after prostate cancer","volume":"17","author":"Lepore","year":"1998","journal-title":"J Soc Clin Psychol"},{"issue":"3","key":"10.1016\/j.cct.2015.03.006_bb0235","first-page":"173","article-title":"Psychosocial factors contributing to inflammatory bowel disease activity and health-related quality of life","volume":"8","author":"Faust","year":"2012","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.cct.2015.03.006_bb0240","series-title":"Measures in health psychology: a user's portfolio","article-title":"Generalized self-efficacy scale, causal and control beliefs","author":"Schwarzer","year":"1995"},{"issue":"5","key":"10.1016\/j.cct.2015.03.006_bb0245","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3200\/JRLP.139.5.439-457","article-title":"The general self-efficacy scale: multicultural validation studies","volume":"139","author":"Luszczynska","year":"2005","journal-title":"J Psychol"},{"issue":"1","key":"10.1016\/j.cct.2015.03.006_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/h0092976","article-title":"Generalized expectancies for internal versus external control of reinforcement","volume":"80","author":"Rotter","year":"1966","journal-title":"Psychol Monogr"},{"issue":"3","key":"10.1016\/j.cct.2015.03.006_bb0255","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4103\/0971-4065.83729","article-title":"Anxiety, locus of control, and coping strategies among end-stage renal disease patients undergoing maintenance hemodialysis","volume":"21","author":"Kohli","year":"2011","journal-title":"Indian J Nephrol"},{"issue":"3 Pt 2","key":"10.1016\/j.cct.2015.03.006_bb0260","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2466\/pr0.1991.69.3f.1075","article-title":"Smoking-specific locus of control","volume":"69","author":"Bunch","year":"1991","journal-title":"Psychol Rep"},{"issue":"4","key":"10.1016\/j.cct.2015.03.006_bb0265","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/1097-4679(198407)40:4<897::AID-JCLP2270400405>3.0.CO;2-P","article-title":"Locus of control, repression\u2013sensitization, and psychological disorder in chronic pain patients","volume":"40","author":"McCreary","year":"1984","journal-title":"J Clin Psychol"},{"issue":"8","key":"10.1016\/j.cct.2015.03.006_bb0270","first-page":"1571","article-title":"The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial","volume":"91","author":"Irvine","year":"1996","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.cct.2015.03.006_bb0275","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1097\/MIB.0000000000000199","article-title":"eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis","volume":"20","author":"Pedersen","year":"2014","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.cct.2015.03.006_bb0280","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0016-5085(90)90002-I","article-title":"Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","volume":"98","author":"Modigliani","year":"1990","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cct.2015.03.006_bb0285","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ibd.20312","article-title":"Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings","volume":"14","author":"Sipponen","year":"2008","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1016\/j.cct.2015.03.006_bb0290","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/dia.2008.0283","article-title":"WellDoc mobile diabetes management randomized controlled trial: change in clinical and behavioral outcomes and patient and physician satisfaction","volume":"10","author":"Quinn","year":"2008","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.cct.2015.03.006_bb0295","series-title":"Wireless quick facts: December 2006","year":"2009"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714415000610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714415000610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T19:14:45Z","timestamp":1651691685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714415000610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":59,"alternative-id":["S1551714415000610"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2015.03.006","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD): Design and implementation of randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2015.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}